Pharmacological effects of acute and accumulated salbutamol in relation to doping analysis
Conditions
Interventions
Trade Name: Ventoline
Product Name: Ventoline
Pharmaceutical Form: Oral solution
INN or Proposed INN: SALBUTAMOL SULFATE
CAS Number: 510
Sponsors
Bispebjerg University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Male and female aged 18-45 years • Physical active, at least 2 times a week • VO2-max at least 45 ml/min/kg (women) and 50 ml/min/kg (men) • Non-smokers • No daily use of medicine Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: Hypersensitivity towrads the active substance or any one of the other substances within the medicine. Coronary heart desiease, asthma or other cronical disease Not able to get doctors permission to participate in the trial after an objective examination Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The aim is to investigate the pharmaco dynamics and kinetics for acute and accumulated salbutamol in relation to doping analysis;Secondary Objective: Not applicable; Primary end point(s): Urine concentrations of salbutamol Performance test (wingate) ;Timepoint(s) of evaluation of this end point: Spring 2019 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable | — |
Countries
Denmark
Contacts
Public ContactMorten Hostrup
Bispebjerg University Hospital
Outcome results
None listed